Q-omics provides the consensus-scored VN1R84P profile across patient tissues and cancer cell-line models. VN1R84P expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, VN1R84P is differentially expressed in 4, with the highest sampling consensus in BRCA. Additionally, VN1R84P RNA expression shows 10,982 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, BRCA, and UVM as cancer lineages where VN1R84P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for VN1R84P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes VN1R84P survival associations across molecular data types. VN1R84P RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible VN1R84P RNA expression–survival associations across cancer types. High VN1R84P expression shows unfavorable associations in COAD, PAAD, UVM and READ, but favorable associations in HNSC and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for VN1R84P RNA expression.
This table summarizes VN1R84P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for VN1R84P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. VN1R84P shows higher tumor expression in BRCA, BLCA, LIHC and STAD. The BRCA box plot shows higher VN1R84P RNA expression in tumor versus normal tissue (log2 FC = +0.289, t-test p = .010).
This table shows molecular features associated with VN1R84P in patient tissues and cancer cell lines. In patient samples, VN1R84P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
